Innoviva (INVA) Financials: History & Chart

Innoviva, Inc.(INVA)

Biotechnology · Burlingame, CA

$20.91+0.27 (+1.32%)

Delayed quote: Oct 6, 2026, 12:35 PM EDT

About Innoviva, Inc.

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Burlingame, CA

159 employees

www.inva.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pavel Raifeld

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	443.43M	119.59M	97.99M	118.05M	107.80M	100.28M	88.63M	91.81M	89.51M
Cost of Goods Sold	119.34M	28.98M	22.16M	42.43M	25.78M	10.59M	8.84M	7.17M	9.99M
Gross Profit	324.08M	90.62M	75.83M	75.61M	82.02M	89.69M	79.79M	84.64M	79.52M
Gross Profit Margin	73.1%	75.8%	77.4%	64.1%	76.1%	89.4%	90.0%	92.2%	88.8%
Total Operating Expenses	161.51M	39.76M	37.68M	36.62M	47.45M	138.44M	121.22M	41.50M	29.77M
Research & Development	28.66M	5.19M	5.24M	4.55M	13.67M	7.98M	4.40M	3.67M	3.55M
Selling, General & Administrative	126.49M	34.57M	32.44M	32.07M	27.41M	26.41M	27.49M	31.33M	26.22M
Operating Income (EBIT)	162.57M	50.85M	38.15M	38.99M	34.58M	-48.75M	-41.43M	43.14M	49.75M
Operating Margin	36.7%	42.5%	38.9%	33.0%	32.1%	-48.6%	-46.7%	47.0%	55.6%
Income Before Tax (EBT)	419.40M	-108.02M	234.56M	195.04M	97.82M	72.60M	-38.59M	24.69M	6.85M
Interest Income	30.21M	7.60M	10.99M	6.15M	5.47M	4.92M	4.54M	5.77M	5.50M
Interest Expense	18.23M	5.47M	5.44M	3.31M	4.01M	4.66M	4.71M	4.75M	5.81M
Other Income/Expense	256.82M	-158.88M	196.41M	156.05M	63.24M	121.35M	2.84M	-18.45M	-42.90M
Net Income	357.24M	-83.42M	186.59M	164.15M	89.91M	63.69M	-46.58M	20.33M	1.21M
Income Tax Expense	62.16M	-24.60M	47.97M	30.88M	7.91M	8.91M	8.00M	4.36M	5.64M
Net Profit Margin	80.6%	-69.8%	190.4%	139.1%	83.4%	63.5%	-52.6%	22.1%	1.4%
EBITDA	252.35M	113.81M	48.20M	49.11M	41.23M	-42.20M	-34.95M	49.65M	56.26M
EBITDA Margin	56.9%	95.2%	49.2%	41.6%	38.2%	-42.1%	-39.4%	54.1%	62.9%
Depreciation & Amortization	89.78M	62.96M	10.04M	10.12M	6.65M	6.55M	6.47M	6.51M	6.51M
EPS Basic	4.87	-1.14	2.52	2.19	1.30	1.01	-0.74	0.32	0.02
EPS Diluted	4.10	-1.14	2.22	1.94	1.08	0.77	-0.74	0.24	0.02
Weighted Average Basic Shares	73.42M	73.42M	74.16M	74.80M	69.06M	62.87M	62.71M	62.73M	62.57M
Weighted Average Diluted Shares	73.42M	73.42M	84.85M	85.26M	84.96M	84.45M	62.71M	84.20M	62.95M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	425.13M	358.71M	310.46M	331.34M	391.87M	336.79M	261.02M	261.00M
Cost of Goods Sold	117.61M	36.60M	42.64M	13.79M	0.00	0.00	0.00	0.00
Gross Profit	307.52M	322.11M	267.82M	317.55M	391.87M	336.79M	261.02M	261.00M
Gross Profit Margin	72.3%	89.8%	86.3%	95.8%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	143.77M	155.25M	153.94M	110.55M	16.76M	15.67M	14.66M	22.75M
Research & Development	30.60M	13.65M	33.92M	41.43M	576K	1.79M	N/A	N/A
Selling, General & Administrative	113.17M	115.69M	98.23M	63.54M	16.19M	13.88M	14.66M	17.05M
Operating Income (EBIT)	163.75M	166.87M	113.89M	207.00M	375.10M	321.12M	246.36M	238.25M
Operating Margin	38.5%	46.5%	36.7%	62.5%	95.7%	95.3%	94.4%	91.3%
Income Before Tax (EBT)	326.86M	37.39M	194.10M	286.95M	445.28M	354.25M	232.90M	210.25M
Interest Income	21.09M	19.14M	15.82M	6.37M	1.84M	1.52M	5.54M	1.66M
Interest Expense	16.70M	22.21M	19.16M	15.79M	19.07M	18.33M	18.66M	23.95M
Other Income/Expense	163.12M	-129.48M	80.21M	79.95M	70.17M	33.12M	-13.46M	-28.00M
Net Income	271.17M	23.39M	179.72M	213.92M	265.85M	224.40M	157.29M	395.06M
Income Tax Expense	55.70M	14.00M	14.38M	66.69M	76.44M	60.43M	41.90M	-196.07M
Net Profit Margin	63.8%	6.5%	57.9%	64.6%	67.8%	66.6%	60.3%	151.4%
EBITDA	203.97M	192.77M	135.67M	212.58M	388.94M	321.12M	260.23M	252.12M
EBITDA Margin	48.0%	53.7%	43.7%	64.2%	99.3%	95.3%	99.7%	96.6%
Depreciation & Amortization	40.23M	25.90M	21.78M	5.58M	13.83M	0.00	13.87M	13.87M
EPS Basic	4.02	0.37	2.92	3.07	3.24	2.21	1.56	3.92
EPS Diluted	3.30	0.36	2.20	2.37	2.87	2.02	1.43	3.53
Weighted Average Basic Shares	67.39M	62.73M	65.44M	69.64M	82.06M	101.32M	101.15M	100.85M
Weighted Average Diluted Shares	84.76M	74.19M	86.88M	95.25M	94.31M	113.55M	113.41M	113.41M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.